Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/100860
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Paiva, Luís | - |
dc.contributor.author | Coelho, José | - |
dc.contributor.author | Barra, Sérgio | - |
dc.contributor.author | Costa, Marco | - |
dc.contributor.author | Sargento-Freitas, João | - |
dc.contributor.author | Cunha, Luís | - |
dc.contributor.author | Gonçalves, Lino | - |
dc.date.accessioned | 2022-07-15T10:21:08Z | - |
dc.date.available | 2022-07-15T10:21:08Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 08702551 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/100860 | - |
dc.description.abstract | Introduction: This study aimed to evaluate the performance of non-vitamin K antagonist oral anticoagulation (NOAC) in patients with previous stroke and non-valvular atrial fibrillation (AF) compared with left atrial appendage occlusion (LAAO) in primary and secondary stroke prevention settings. Methods: This was a prospective, single-center, non-randomized cohort study of 302 consecutive patients with non-valvular AF and at high risk for stroke. Two treatment strategies were compared: LAAO (n=91) and long-term treatment with NOAC (n=149). The primary outcome was the composite endpoint of death, stroke and major bleeding. Propensity score and cause-ofdeath analyses were performed to compare outcomes. Results: In a mean follow-up of 13 months, there were 30 deaths (LAAO 8.8% vs. NOAC 14.8%), five strokes (LAAO 1.1% vs. NOAC 2.7%) and six major bleeds (LAAO 1.1% vs. NOAC 3.4%). There was a non-significant trend for a lower incidence of the primary endpoint in the LAAO group (11.0% vs. 20.9%; HR 0.42, 95% CI 0.17-1.05, p=0.064). Considering only secondary prevention LAAO patients (34.1% of the LAAO group), there was also a non-significant lower incidence of the primary endpoint (LAAO 6.5% vs. 20.9%; HR 0.30, 95% CI 0.07-1.39, p=0.12). While about a fifth of LAAO patients stopped antiplatelet treatment six months after device implantation due to recurrent minor bleeding, no adverse cardiovascular event or major bleeding occurred in this subset of patients. | pt |
dc.language.iso | eng | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | Antiplatelet | pt |
dc.subject | Left atrial appendage | pt |
dc.subject | Occlusion | pt |
dc.subject | Oral anticoagulation | pt |
dc.title | Non-vitamin K antagonist oral anticoagulation versus left atrial appendage occlusion for primary and secondary stroke prevention after cardioembolic stroke | pt |
dc.type | article | - |
degois.publication.firstPage | 357 | pt |
degois.publication.lastPage | 365 | pt |
degois.publication.issue | 5 | pt |
degois.publication.title | Revista Portuguesa de Cardiologia | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.repc.2020.07.021 | pt |
degois.publication.volume | 40 | pt |
dc.date.embargo | 2021-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.openairetype | article | - |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.cerifentitytype | Publications | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0001-9255-3064 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0870255121001062-main.pdf | 685.76 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Nov 17, 2022
WEB OF SCIENCETM
Citations
4
checked on Nov 15, 2022
Page view(s)
100
checked on Aug 28, 2024
Download(s)
54
checked on Aug 28, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License